Cargando…

Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings

Biphasic insulin aspart 30 (BIAsp 30) includes 30% soluble rapid-acting insulin aspart (IAsp) along with an intermediate-acting 70% protaminated IAsp that provides coverage of prandial and basal insulin in a single injection. As BIAsp 30 has been available internationally for 10 years, this review p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liebl, Andreas, Prusty, Vinay, Valensi, Paul, Kawamori, Ryuzo, Christiansen, Jens Sandahl, Palmer, Andrew J., Balschmidt, Per, Ligthelm, Robert, Mohan, Viswanathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590411/ https://www.ncbi.nlm.nih.gov/pubmed/22818015 http://dx.doi.org/10.2165/11635490-000000000-00000

Ejemplares similares

Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
por: Gumprecht, J, et al.
Publicado: (2009)

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes
por: Liebl, Andreas, et al.
Publicado: (2018)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
por: Valensi, Paul
Publicado: (2009)

Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen
por: Haddad, Jihad, et al.
Publicado: (2013)

Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study
por: Shah, S, et al.
Publicado: (2009)

Safety, Tolerability, and Efficacy of Insulin Aspart in People with Type 2 Diabetes, as Biphasic Insulin Aspart or with Basal Insulin: Findings from the Multinational, Non-Interventional A(1)chieve Study
por: Hajjaji, Issam, et al.
Publicado: (2014)

Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement
por: Brito, Miguel, et al.
Publicado: (2011)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009)

A commentary on the “consensus statement” regarding the use of BIAsp30
por: Kawamori, Ryuzo
Publicado: (2010)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A(1)chieve study
por: Sahoo, Abhay Kumar, et al.
Publicado: (2013)

Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving biphasic insulin aspart 30 or biphasic human insulin 30
por: Ohta, Akio, et al.
Publicado: (2011)

Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes
por: Franek, E., et al.
Publicado: (2015)

Clinical experience of switching from biphasic human insulin to biphasic insulin aspart 30 in Indian patients with type 2 diabetes in the A(1)chieve study
por: Das, A. K., et al.
Publicado: (2015)

Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A(1)chieve Sub-Analysis
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2013)

Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy
por: Mohan, Viswanathan, et al.
Publicado: (2022)

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
por: Niskanen, Leo, et al.
Publicado: (2012)

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
por: Onishi, Yukiko, et al.
Publicado: (2016)

Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring
por: Margaritidis, Charalampos, et al.
Publicado: (2021)

Learn ECMAScript: discover the latest ECMAScript features in order to write cleaner code and learn the fundamentals of JavaScript
por: Mohan, Mehul, et al.
Publicado: (2018)

Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes
por: Raja-Khan, Nazia, et al.
Publicado: (2007)

Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial
por: Xu, Shaoyong, et al.
Publicado: (2016)

Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective
por: Evans, Marc, et al.
Publicado: (2016)

Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes
por: Ma, Zhulin, et al.
Publicado: (2014)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
por: Luo, Qiong, et al.
Publicado: (2022)

28‐week, randomized, multicenter, open‐label, parallel‐group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice‐daily injections vs twice‐daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2010)

Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature
por: Kumar, Ajay
Publicado: (2016)

Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
por: Güler, Serdar, et al.
Publicado: (2009)

Switching from basal or basal-bolus insulin to biphasic insulin aspart 30: Results from the Indian cohort of the A(1) chieve study
por: Bhattacharyya, Arpandev, et al.
Publicado: (2014)

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study
por: Farshchi, Amir, et al.
Publicado: (2016)

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial
por: Yang, Wenying, et al.
Publicado: (2019)

Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A(1)chieve® observational study
por: Yang, Wenying, et al.
Publicado: (2014)

Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market
por: Murthy, Sreenivasa, et al.
Publicado: (2021)

Biphasic human insulin 30 thrice daily, is it reasonable?
por: Saadeh, Nesreen A., et al.
Publicado: (2020)

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Reach further
por: Christiansen, Jens Sandahl
Publicado: (2012)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Agadir cohort of the A(1)chieve study
por: Boussouf, Hicham, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Marrakech cohort of the A(1)chieve study
por: Nawal, El Ansari
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Casablanca cohort of the A(1)chieve study
por: Farouqi, Ahmed, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Saiss cohort of the A(1)chieve study
por: Ajdi, Farida
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yanbu cohort of the A(1)chieve study
por: El Harby, Moody, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kkd7amiaeu6e08bearu0639ssk